| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/11/2000 | US6087370 Methods of treatment using lamellarin-class alkaloids |
| 07/11/2000 | US6087367 Potent inducers of terminal differentiation and methods of use thereof |
| 07/11/2000 | US6087365 Treating drug-resistant malaria in a mammal |
| 07/11/2000 | US6087350 Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| 07/11/2000 | US6087349 Method for blocking neoplastic transformation of cells induced by ras oncogenes |
| 07/11/2000 | US6087337 Treating melanomas or metastases of malignant melanomas by topically administering to mammal at the site of melanoma with a cyclic or linear octapeptide somatostatins |
| 07/11/2000 | US6087304 Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 07/11/2000 | US6087186 Synthetic library of random oligomers, each member comprising an oligomer linked to a microchip encoded with information identifying structure of oligomer; for drug screening |
| 07/11/2000 | US6087173 Antisense modulation of X-linked inhibitor of apoptosis expression |
| 07/11/2000 | US6087169 HKABY60: polynucleotide encoding a helix-loop-helix ubiquitous kinase family polypeptide |
| 07/11/2000 | US6087167 Promoting neuron survival or neurite outgrowth by contacting neurons with an amount of an eck receptor binding protein of specific amino acid sequence |
| 07/11/2000 | US6087164 Introducing polynucleotide comprising a regulatory sequence, derived from a genomically imprinted gene specifically expressed in tumor cell, linked to a heterologous sequence encoding cytotoxic product; antitumor agents; gene therapy |
| 07/11/2000 | US6087160 Programmed cell death genes and proteins |
| 07/11/2000 | US6087122 Polynucleotide sequence which codes a mammalian polypeptide synthetases; for diagnosis, evaluation, prevention, and treatment of physiological defects |
| 07/11/2000 | US6087110 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| 07/11/2000 | US6086874 Kit comprising an interleukin-6 (il-6) antagonist such as antibody to il-6, antibody to il-6 receptor, and antibody to gp130 protein, an antitumor agent such as cisplatin, and a carrier; antagonist and antitumor agent not physically bonded |
| 07/11/2000 | US6086873 Irradiating an antibody with ultraviolet light to expose a reactive sulfhydryl of the antibody without changing its biological function, administering to a host to generate a greater immune response than against the native antibody |
| 07/11/2000 | US6086865 O-chloracetylcarbamoylfumagillol and interferon; synergistic angiogenesis inhibitory effect |
| 07/11/2000 | US6086850 Calcitonin receptor binding reagents |
| 07/11/2000 | CA2030519C Acryloyl substituted pyrrole derivatives |
| 07/11/2000 | CA1341050C Neurite growth regulatory factors |
| 07/06/2000 | WO2000039716A2 Arylpropenylimidazoles as farnesyl-protein transferase inhibitors |
| 07/06/2000 | WO2000039589A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | WO2000039327A1 Peptidoglycan recognition proteins |
| 07/06/2000 | WO2000039317A1 Gene transfer vector for the diagnosis and therapy of malign tumors |
| 07/06/2000 | WO2000039311A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | WO2000039292A2 Antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen 4 (vla-4) in human cells |
| 07/06/2000 | WO2000039283A1 Use of cd40 engagement to alter t cell receptor usage |
| 07/06/2000 | WO2000039275A2 Multiple shear stress responsive elements (ssre) and methods of use thereof |
| 07/06/2000 | WO2000039159A1 Superantigens |
| 07/06/2000 | WO2000039153A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same |
| 07/06/2000 | WO2000039148A1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases |
| 07/06/2000 | WO2000039140A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same |
| 07/06/2000 | WO2000039136A2 Human brainiac-5 |
| 07/06/2000 | WO2000039130A2 Prenyl transferase inhibitors |
| 07/06/2000 | WO2000039129A1 Immunosuppressive effects of pteridine derivatives |
| 07/06/2000 | WO2000039128A1 5ht1 antagonists for antidepressant therapy |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039119A1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2000 | WO2000039101A1 Pyrimidine compounds |
| 07/06/2000 | WO2000039088A1 Glucagon antagonists/inverse agonists |
| 07/06/2000 | WO2000039087A2 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors |
| 07/06/2000 | WO2000039083A2 Pyrazole compounds and uses thereof |
| 07/06/2000 | WO2000039082A2 1,2-annelated quinoline derivatives |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000039070A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038785A2 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | WO2000038734A1 Anthraquinone anticancer drugs |
| 07/06/2000 | WO2000038733A1 Peptidic product, process and composition |
| 07/06/2000 | WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 07/06/2000 | WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia |
| 07/06/2000 | WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 07/06/2000 | WO2000038716A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 07/06/2000 | WO2000038713A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | WO2000038710A2 Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer |
| 07/06/2000 | WO2000038709A1 Treatment of hyperproliferative disorders using casein kinase i |
| 07/06/2000 | WO2000038706A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 07/06/2000 | WO2000038697A1 Treatment and prevention of hiv and other viral infections |
| 07/06/2000 | WO2000038694A1 Medicinal compositions for treating osseous lesion in multiple myeloma |
| 07/06/2000 | WO2000038687A1 Protease inhibitors |
| 07/06/2000 | WO2000038676A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 07/06/2000 | WO2000038674A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 07/06/2000 | WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038660A2 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 07/06/2000 | WO2000038623A1 Cosmetic or medical preparation for topical use |
| 07/06/2000 | WO2000038519A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/06/2000 | WO2000038515A1 Peptide mimics useful for treating disease |
| 07/06/2000 | WO2000022124A3 Methods and compositions to induce antitumor response |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020023A3 Null igf for the treatment of cancer |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO1999066030A9 Dap-kinase related protein |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999054447A3 Human nucleic acid sequences of bladder tumour tissue |
| 07/06/2000 | WO1999053040A3 Human nucleic acid sequences from ovarian tumour tissue |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | WO1999051727A3 Human nucleic acid sequences of normal ovary tissue |
| 07/06/2000 | WO1999047655A3 Human nucleic acid fragments with heightened expression in normal breast tissue |
| 07/06/2000 | WO1999046375A3 Human nucleic acid sequences from prostate tissue |
| 07/06/2000 | WO1999046374A3 Human nucleic acid sequences from prostate tumour tissue |
| 07/06/2000 | WO1999041282A8 Therapeutic uses of keratinocyte growth factor-2 |
| 07/06/2000 | WO1999040119A9 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 07/06/2000 | DE19860642A1 Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen An antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen-4 (VLA-4) in human cells |
| 07/06/2000 | DE19860602A1 Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren Gene transfer vector for the diagnosis and therapy of malignant tumors |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358094A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | CA2358047A1 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds |
| 07/06/2000 | CA2357042A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356885A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same |
| 07/06/2000 | CA2356777A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same |
| 07/06/2000 | CA2356756A1 Prenyl transferase inhibitors |
| 07/06/2000 | CA2356755A1 Superantigens |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |